Cannon Global Investment Management LLC Makes New $545,000 Investment in Amedisys, Inc. (NASDAQ:AMED)

Cannon Global Investment Management LLC acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 6,000 shares of the health services provider's stock, valued at approximately $545,000.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Amedisys by 0.3% during the fourth quarter. Vanguard Group Inc. now owns 3,216,120 shares of the health services provider's stock worth $291,992,000 after acquiring an additional 10,817 shares during the last quarter. Westchester Capital Management LLC boosted its stake in Amedisys by 9.5% in the 3rd quarter. Westchester Capital Management LLC now owns 1,118,802 shares of the health services provider's stock worth $107,976,000 after purchasing an additional 97,476 shares in the last quarter. Alpine Associates Management Inc. grew its position in Amedisys by 3.2% during the 4th quarter. Alpine Associates Management Inc. now owns 888,120 shares of the health services provider's stock worth $80,632,000 after purchasing an additional 27,403 shares during the last quarter. Wealthfront Advisers LLC acquired a new position in Amedisys during the 4th quarter valued at approximately $72,970,000. Finally, Magnetar Financial LLC raised its holdings in shares of Amedisys by 0.3% in the fourth quarter. Magnetar Financial LLC now owns 637,443 shares of the health services provider's stock worth $57,873,000 after buying an additional 1,835 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Stephens reiterated an "equal weight" rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $101.00.

Remove Ads

Amedisys Stock Performance

AMED stock traded down $0.20 during trading on Friday, hitting $92.70. 221,184 shares of the company traded hands, compared to its average volume of 396,120. Amedisys, Inc. has a 1 year low of $82.15 and a 1 year high of $98.95. The company has a market cap of $3.04 billion, a PE ratio of 36.79, a P/E/G ratio of 1.78 and a beta of 0.76. The stock's 50-day simple moving average is $92.28 and its 200 day simple moving average is $92.47. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19.

Amedisys (NASDAQ:AMED - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The health services provider reported $0.96 EPS for the quarter, missing analysts' consensus estimates of $1.05 by ($0.09). Amedisys had a return on equity of 12.20% and a net margin of 3.57%. The firm had revenue of $598.05 million for the quarter, compared to analyst estimates of $602.38 million. On average, equities analysts expect that Amedisys, Inc. will post 4.4 earnings per share for the current fiscal year.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.